DPP-4 inhibitors carry a minimal risk of hypoglycemia and gastrointestinal symptoms
COA documentation is thorough and cold-chain shipping protects product integrity. Exceptional quality control & customer service
Weight Loss: In phase III trials, weight loss with the use of exenatide averaged between 0.9 and 2.8 kg over a 30-month time frame, with more weight loss associated when exenatide is added to existing metformin therapy
Safety, Eligibility, and When to Seek More Intensive Screening Both platforms screen for GLP-1 contraindications: personal or family history of medullary thyroid cancer, multiple endocrine neoplasia type 2, severe pancreatitis, and severe kidney disease
Retatrutide belongs to a new class of medicines called multi-agonist peptides
It is essential to be aware of the potential side effects and know when to seek help if they occur